Gemini Therapeutics
- Total Funding$44.5 M
OverviewSuggest Edit
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. The Company's therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and its broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
| Type | Private | |
| Founded | 2015 | |
| HQ | Cambridge, MA, US | Map |
| Website | geminitherapeutics.com | |
| Employee Ratings |
Latest Updates
| Employees (est.) (Apr 2022) | 34 | (-5%) |
| Cybersecurity rating | A | More |
Key People/Management at Gemini Therapeutics
David Lubner
Independent Director
Jason Meyenburg
Chief Executive Officer
Samuel Barone
Chief Medical Officer
Brian Piekos
Chief Financial Officer
Scott Lauder
Chief Technology Officer
Precillia Redmond
Chief People Officer
Gemini Therapeutics Office Locations
Gemini Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
300 One
Gemini Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Gemini Therapeutics total Funding | $44.5 m |
Gemini Therapeutics latest funding size | $42.5 m |
Time since last funding | 5 years ago |
Gemini Therapeutics investors | Atlas Venture, Lightstone Ventures, OrbiMed |
Gemini Therapeutics's latest funding round in October 2017 was reported to be $42.5 m. In total, Gemini Therapeutics has raised $44.5 m
Gemini Therapeutics Cybersecurity Score
Gemini Therapeutics Online and Social Media Presence
531 Twitter followers
Gemini Therapeutics has 531 Twitter Followers. The number of followers has increased 0.2% month over month and increased 3.3% quarter over quarter
Gemini Therapeutics's Trends
Gemini Therapeutics News and Updates
December 15, 2021
Thinking about buying stock in BELLUS Health, Gemini Therapeutics, BlackBerry, Reliance Global Group, or Ocugen?
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GMTX, BB, RELI, and OCGN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Gemini Therapeutics Blogs
February 01, 2021
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
Topline Data Expected in 2H 2021
The post Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy appeared first on Gemini Therapeutics.
January 07, 2021
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene Variants
CAMBRIDGE, Mass. – January 7, 2021 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that GEM103, the Company’s investigational treatment for dry AMD, has been granted Fa…
November 13, 2020
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment for dry AMD, met all its endpoints.
The post Gem…
November 10, 2020
Gemini Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. – November 10, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled …
October 15, 2020
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration
CAMBRIDGE, Mass. and SAN FRANCISCO – October 15, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company spo…
September 10, 2020
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration
Enrollment completed in Phase 1 SAD study in patients with high-risk genetic variants for dry AMD. Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD. CAMBRIDGE, Mass. —(BUSINESS WI…
Gemini Therapeutics Frequently Asked Questions
When was Gemini Therapeutics founded?
Gemini Therapeutics was founded in 2015.
Who are Gemini Therapeutics key executives?
Gemini Therapeutics's key executives are David Lubner, Jason Meyenburg and Samuel Barone.
How many employees does Gemini Therapeutics have?
Gemini Therapeutics has 34 employees.
Who are Gemini Therapeutics competitors?
Competitors of Gemini Therapeutics include Othram, Cradle Genomics and Heart Genetics.
Where is Gemini Therapeutics headquarters?
Gemini Therapeutics headquarters is located at 300 One, Cambridge.
Where are Gemini Therapeutics offices?
Gemini Therapeutics has an office in Cambridge.
How many offices does Gemini Therapeutics have?
Gemini Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies